Pentylenetetrazole - Balance Therapeutics

Drug Profile

Pentylenetetrazole - Balance Therapeutics

Alternative Names: BTD-001

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Balance Therapeutics
  • Class Antihypotensives; Azepines; Nootropics; Respiratory stimulants; Small molecules
  • Mechanism of Action Central nervous system stimulants; GABA-A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Hypersomnia; Narcolepsy
  • No development reported Down syndrome

Most Recent Events

  • 04 Apr 2017 Balance Therapeutics plans a phase I trial in healthy male volunteers in USA (NCT03107013)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Down syndrome(In volunteers) in Australia (PO, Liquid)
  • 01 Sep 2015 Phase-II clinical trials in Hypersomnia in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top